...
首页> 外文期刊>Cancer investigation >Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas
【24h】

Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas

机译:培美曲塞联合顺铂联合外照射治疗局部晚期或转移性食管或胃食管交界癌患者的第一阶段研究

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15-35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500mg/m(2).
机译:目的:在局部晚期或转移性食管和胃食管连接患者中,建立每周两次培美曲塞(PEM)与每周顺铂(CDDP)和标准剂量外照射(EBRT)结合时的最大耐受剂量(MTD)和安全性概况(GEJ)癌。方法:我们进行了一项开放标签,单一机构的I期剂量递增研究,旨在评估多达15-35名患有晚期或转移性食管癌和GEJ癌的患者。结果:10例患者接受了每两周一次的PEM,每周一次的CDDP和EBRT治疗。确定每两周一次PEM的MTD为500mg / m(2)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号